GlassScriptPhysician profile
Annette Bulas
NPI 1326102286
$2,475.24
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $313 · 2021: $630 · 2022: $425 · 2023: $434 · 2024: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $753.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $369.60 | 2019-2024 | Cequa, Xelpros |
| Bausch & Lomb Americas INC. | $292.46 | 2022-2024 | Xiidra, Miebo, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $270.52 | 2019-2021 | |
| Alcon Vision LLC | $261.05 | 2019-2023 | Rocklatan, Argos, Eysuvis |
| Allergan, INC. | $202.67 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $170.84 | 2019-2021 | |
| Abbvie INC. | $155.73 | 2022-2024 | Lumigan, Alphagan P |
| Oyster Point Pharma, INC. | $120.48 | 2022-2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $119.76 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $83.04 | 2019-2022 | |
| Biotissue Holdings INC. | $73.45 | 2020-2021 | |
| Coopervision INC. | $57.49 | 2023 | Myday Contact Lens |
| Topcon Healthcare, INC. | $57.19 | 2022 | |
| Sight Sciences, INC. | $36.19 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $25.25 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $24.73 | 2024 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $24.24 | 2019 | |
| Shire North American Group INC | $21.38 | 2019 | |
| Glaukos Corporation | $20.82 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Dompe US, INC. | $19.22 | 2022 | |
| Omeros Corporation | $18.97 | 2019 | |
| Eyevance Pharmaceuticals LLC | $16.86 | 2023 | Flarex |
| Harrow Eye, LLC | $13.90 | 2024 | Iheezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annette Bulas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.